scholarly journals Immune-Therapy in Cutaneous Melanoma – Efficacy Immune Markers

10.5772/23493 ◽  
2012 ◽  
Author(s):  
Monica Neagu ◽  
Carolina Constanti
Keyword(s):  
Cutaneous Melanoma ◽  
Immune Therapy ◽  
Immune Markers

scholarly journals The Integrative Analysis Identifies Three Cancer Subtypes and Stemness Features in Cutaneous Melanoma

2021 ◽  
Vol 7 ◽  
Author(s):  
Xiaoran Wang ◽  
Qi Wan ◽  
Lin Jin ◽  
Chengxiu Liu ◽  
Chang Liu ◽  
...  
Keyword(s):  
Survival Time ◽  
Cutaneous Melanoma ◽  
Immune Therapy ◽  
Low Risk ◽  
The Cancer Genome Atlas ◽  
Recursive Feature Elimination ◽  
Support Vector ◽  
Tumor Purity ◽  
Melanoma Patients ◽  
Immune Score

Background: With the growing uncovering of drug resistance in melanoma treatment, personalized cancer therapy and cancer stem cells are potential therapeutic targets for this aggressive skin cancer.Methods: Multi-omics data of cutaneous melanoma were obtained from The Cancer Genome Atlas (TCGA) database. Then, these melanoma patients were classified into different subgroups by performing "CancerSubtypes" method. The differences of stemness indices (mRNAsi and mDNAsi) and tumor microenvironment indices (immune score, stromal score, and tumor purity) among subtypes were investigated. Moreover, the Least Absolute Shrinkage and Selection Operator (LASSO) and Support Vector Machine-Recursive Feature Elimination (SVM-RFE) algorithms were performed to identify a cancer cell stemness feature, and the likelihood of immuno/chemotherapeutic response was further explored.Results: Totally, 3 specific subtypes of melanoma with different survival outcomes were identified from TCGA. We found subtype 2 of melanoma with the higher immune score and stromal score and lower mRNAsi and tumor purity score, which has the best survival time than the other subtypes. By performing Kaplan–Meier survival analysis, we found that mRNAsi was significantly associated with the overall survival time of melanomas in subtype 2. Correlation analysis indicated surprising associations between stemness indices and subsets of tumor-infiltrating immune cells. Besides, we developed and validated a prognostic stemness-related genes feature that can divide melanoma patients into high- and low-risk subgroups by applying risk score system. The high-risk group has a significantly shorter survival time than the low-risk subgroup, which is more sensitive to CTLA-4 immune therapy. Finally, 16 compounds were screened out in the Connectivity Map database which may be potential therapeutic drugs for melanomas.Conclusion: Thus, our finding provides a new framework for classification and finds some potential targets for the treatment of melanoma.

scholarly journals Management of metastatic cutaneous melanoma: updates in clinical practice

2019 ◽  
Vol 11 ◽  
pp. 175883591985166 ◽  
Author(s):  
Gustavo Schvartsman ◽  
Patricia Taranto ◽  
Isabella C. Glitza ◽  
Sanjiv S. Agarwala ◽  
Michael B. Atkins ◽  
...  
Keyword(s):  
Cutaneous Melanoma ◽  
Cytotoxic T Lymphocyte ◽  
Checkpoint Inhibitors ◽  
Immune Therapy ◽  
Treatment Options ◽  
Single Agent ◽  
Current Data ◽  
Treatment Modalities ◽  
Duration Of Treatment ◽  
Programmed Cell Death 1

In recent years, several drugs have been approved for the treatment of patients with metastatic cutaneous melanoma, completely reshaping the landscape of this aggressive disease. Immune therapy with cytotoxic T-lymphocyte antigen 4 and programmed cell death-1 inhibitors yielded significant and durable responses, achieving long-term disease control in up to 40% of the patients. BRAF inhibitors (BRAFi), in combination with MEK inhibitors, also resulted in improved overall survival compared with single-agent BRAFi in patients with BRAFV600-mutated metastatic melanoma. The optimized sequencing and duration of treatment, however, is yet to be found. In this article, we thoroughly review current data and discuss how to best sequence the various treatment modalities available at present, based on four distinct clinical presentations commonly seen in clinic. In addition, we review treatment options beyond checkpoint inhibitors and targeted therapy, which may be required by patients failing such effective treatments.

Cutaneous melanoma in a patient with neurofibromatosis

1979 ◽  
Vol 115 (7) ◽  
pp. 864-865 ◽  
Author(s):  
M. J. Mastrangelo
Keyword(s):  
Cutaneous Melanoma

Oral Immune Activation by Disgust and Disease-Related Pictures

2015 ◽  
Vol 29 (3) ◽  
pp. 119-129 ◽  
Author(s):  
Richard J. Stevenson ◽  
Deborah Hodgson ◽  
Megan J. Oaten ◽  
Luba Sominsky ◽  
Mehmet Mahmut ◽  
...  
Keyword(s):  
Immune Response ◽  
Immune Responses ◽  
Innate Immune Response ◽  
Negative Control ◽  
Innate Immune ◽  
Innate Immune Responses ◽  
Immune Markers ◽  
Before And After ◽  
Secondary Analyses ◽  
Image Set

Abstract. Both disgust and disease-related images appear able to induce an innate immune response but it is unclear whether these effects are independent or rely upon a common shared factor (e.g., disgust or disease-related cognitions). In this study we directly compared these two inductions using specifically generated sets of images. One set was disease-related but evoked little disgust, while the other set was disgust evoking but with less disease-relatedness. These two image sets were then compared to a third set, a negative control condition. Using a wholly within-subject design, participants viewed one image set per week, and provided saliva samples, before and after each viewing occasion, which were later analyzed for innate immune markers. We found that both the disease related and disgust images, relative to the negative control images, were not able to generate an innate immune response. However, secondary analyses revealed innate immune responses in participants with greater propensity to feel disgust following exposure to disease-related and disgusting images. These findings suggest that disgust images relatively free of disease-related themes, and disease-related images relatively free of disgust may be suboptimal cues for generating an innate immune response. Not only may this explain why disgust propensity mediates these effects, it may also imply a common pathway.

Sign in / Sign up

Export Citation Format

Share Document